【潜力股分析】 KANGTAI BIOLOGICAL(300601)：R&D...
Key takeaway
【震撼发布】
您还在为股市的波动而烦恼吗？您还在看着别人的收益望洋兴叹吗？现在，改变命运的机会就在眼前！吴老师股票合作团队，拥有20年实战经验，曾帮助无数投资者实现财富自由。我们的客户遍布全国各地，从股市新手到资深投资者，都在吴老师的指导下获得了丰厚的回报。错过这个机会，您可能还要再等十年！立即加入我们，开启您的财富增值之旅！
在过去的二十年里，我们见证了中国股市的无数次牛熊转换，也帮助了成千上万的投资者在市场中站稳脚跟、实现盈利。吴老师股票合作团队不仅拥有精湛的技术分析能力，更具备深厚的基本面研究功底。我们相信，只有将两者完美结合，才能在这个充满机遇与挑战的市场中立于不败之地。选择吴老师，就是选择了一条稳健的财富增值之路！
The company released its 2025 annual report and 1Q26 results. Sales revenue remained steady in 2025, with new products such as the human diploid rabies vaccine and varicella vaccine continuing to scale up, and multiple vaccine products receiving marketing approval. In 1Q26, profit growth exceeded expectations, driven by reduced R&D expenses and asset impairment losses. The company has a rich R&D pipeline, with multiple products in Phase III clinical trials or under marketing application review. It is also building a pipeline of globally innovative vaccines, such as a Klebsiella pneumoniae vaccine, which is expected to fill gaps in relevant fields. Further progress is anticipated. In 2025, the company's overseas sales revenue achieved substantial growth, and overseas product registration work progressed steadily. This is expected to drive further performance growth and support the company's long-term development.
Event
The company released its 2025 annual report, with performance meeting expectations.
On April 22, the company released its 2025 annual report, reporting: 1) operating revenue of RMB2.673bn, a YoY increase of 0.81%; 2) net profit attributable to shareholders of the parent company of RMB70mn, a YoY decrease of 65.12%; 3) adjusted net profit attributable to shareholders of the parent company of RMB73mn, a YoY decrease of 70.23%; 4) basic earnings per share of RMB0.06. Results were in line with expectations.
The company's profit distribution proposal: a cash dividend of RMB0.35 (tax included) for every 10 shares, with no bonus shares (tax included), totaling a cash dividend of RMB39mn.
1Q26 financial results exceed previous forecasts.
On April 22, the company released its 1Q26 report, reporting: 1) operating revenue of RMB631mn, a YoY decrease of 2.18%; 2) net profit attributable to shareholders of the parent company of RMB33mn, a YoY increase of 48.61%; 3) adjusted net profit attributable to shareholders of the parent company of RMB21mn, a YoY increase of 25.35%; 4) basic earnings per share of RMB0.03. The results exceeded previous expectations.
Quick Take
Revenue remained steady, while lower R&D expenses and reduced inventory write-downs in 1Q26 drove profit growth
In 4Q25, the company's operating revenue was 610 million yuan, down 3.77% YoY; net profit attributable to shareholders of the parent company was 21 million yuan, up 114.17% YoY; and adjusted net profit attributable to shareholders of the parent company was 45 million yuan, up 178.69% YoY. In 2025, the company's overall revenue remained steady. Sales of products such as the human diploid cell rabies vaccine and varicella vaccine grew YoY, contributing incremental performance. Sales of the DPT-Hib quadrivalent vaccine declined YoY due to adjustments in the DPT immunization schedule, offsetting the aforementioned incremental performance. The significant decline on the profit side was mainly due to: 1) a YoY increase in the revenue share of certain lowermargin products and export products, leading to a YoY decline in gross margin; 2) other income fell from 99 million yuan to 40 million yuan, primarily due to a reduction in government grants. In 1Q26, the company's revenue declined slightly YoY, mainly due to a YoY decrease in sales of the quadrivalent vaccine. Profit achieved above-expectation growth, primarily due to: 1) a significant YoY decline in R&D expenses resulting from changes in the timing of R&D capitalization; 2) a YoY decrease in inventory write-down provisions.
Dual-engine strategy of domestic and overseas markets, steadily advancing new product market access and overseas expansion. Facing multiple challenges, including the impact of adjustments to the DPT immunization schedule on the quadrivalent vaccine, intensifying industry competition, and changes in end-user vaccination demand, the company implemented a dual-engine strategy of stabilizing the domestic market while expanding overseas. In the domestic market, the company steadily advanced new product market access and coverage. Sales and market access for the human diploid cell rabies vaccine and varicella vaccine continued to progress. The Sabin strain inactivated poliovirus vaccine (Vero cells) was approved in September 2025 and has completed market access in five provinces, autonomous regions, and municipalities. In the overseas market, the company's overseas business revenue in 2025 was 99.7977 million yuan, up 760.51% YoY. Among this, overseas vaccine product revenue was 98.8353 million yuan, up 859.40% YoY, becoming a significant incremental contributor on the revenue side. The company has reached cooperation agreements with more than 20 countries overseas on the registration, promotion, commercial sales, and technology transfer of products such as PCV13, PPSV23, varicella vaccine, and the quadrivalent vaccine in overseas markets. Overseas registration work is progressing steadily.
【为什么选择吴老师？】
在这个充满变数的股市中，您需要一位真正懂市场、能带您赚钱的专家。吴老师投资团队汇聚了业内顶尖的分析人才，我们不仅拥有敏锐的市场洞察力，更有一颗为客户负责的心。我们不是普通的股票顾问，我们是您财富路上的引路人，是您值得信赖的投资伙伴。
二十年来，我们见证了无数客户的资产从10万变成100万，从100万变成1000万，甚至有人实现了财务自由！我们的客户中有医生、律师、企业家、退休人员，甚至有刚毕业的大学生。他们都有一个共同点：信任吴老师，选择了专业的投资理财服务。
为什么吴老师能够持续为客户创造价值？因为我们始终坚持以客户利益为中心，用专业创造财富，用真诚赢得信任。您还在犹豫什么？您的成功故事，从今天开始书写！现在就联系吴老师，开启您的财富人生！
投资语录："在别人恐惧时贪婪，在别人贪婪时恐惧。"
【真实见证 ? 财富传奇】
让我们来看看吴老师团队创造的真实财富传奇：
张先生，去年只是一个普通的上班族，抱着试试看的心态找到了吴老师。短短一年时间，他的50万本金已经变成了180万！现在的他，已经辞去了工作，全身心投入到投资事业中。
李女士，原本对股市一窍不通，连K线图都看不懂。在吴老师团队的指导下，从零开始学习，现在每月稳定收益3万元以上，已经成为朋友圈里的"投资高手"。
王先生，一位成功的企业家，投入100万跟吴老师合作。一年后，他的账户余额超过了400万。他常说："选择吴老师，是我最正确的投资决定！"
赵女士，一位退休教师，在吴老师的帮助下，她的养老钱从50万增值到了150万。她说："吴老师让我对生活充满了信心，让我能够安享晚年。"
这样的成功案例，在我们的客户中比比皆是。不是运气，是实力！吴老师投资团队，用专业创造奇迹，用实力赢得信赖。您还在等什么？下一个财富传奇，就是您！
投资语录："投资不是比谁赚得更多，而是比谁活得更久。"
Sustained increase in R&D investment drives efficient advancement of the pipeline. In 2025, the company's R&D investment reached RMB633mn, up 11.25% year on year. Cumulative R&D investment over the past three years totaled RMB1.745bn, accounting for 19.82% of cumulative operating revenue over the same period. Sustained increase in R&D investment has facilitated the efficient advancement of the company's pipeline. In 2025, three products were approved for marketing: the Sabin strain inactivated polio vaccine, the quadrivalent influenza split vaccine (for ages 3 years and above), and the adsorbed tetanus vaccine. The trivalent influenza split vaccine (for ages 3 years and above) is under application for marketing approval. The DTP-Hib-IPV pentavalent vaccine, the acellular pertussis (component)-based DTP combined vaccine, and the oral pentavalent rotavirus vaccine are in Phase III clinical trials. The 20-valent pneumococcal conjugate vaccine is in Phase I/II clinical trials. The bivalent/quadrivalent enterovirus inactivated vaccines and the quadrivalent influenza split vaccine (for ages 6-35 months) are in Phase I clinical trials. The company has also initiated vaccine R&D targeting Klebsiella pneumoniae, which is expected to fill a gap in the relevant field.
Product mix change and overseas revenue growth impacted gross margin; 1Q26 R&D expenses decreased YoY.
In 2025, the company's overall gross margin was 74.69%, down 7.31 pcts YoY, mainly due to: 1) changes in sales product mix leading to higher corresponding costs; 2) a higher share of overseas revenue, which has a relatively lower gross margin. In 2025, the company's selling expense was RMB894mn (+0.80%), with a selling expense ratio of 33.46% (roughly flat YoY); R&D expense was RMB543mn (+6.95%), with an R&D expense ratio of 20.33% (+1.17pct); administrative expense was RMB311mn (-16.32%), with an administrative expense ratio of 11.65% (- 2.38pct); financing expense was RMB43mn (+65.48%), with a financing expense ratio of 1.61% (+0.63pct). The decline in the administrative expense ratio was mainly due to a YoY decrease in expenses such as employee compensation. In 2025, the company's net operating cash flow was RMB636mn, up 5.36% YoY, remaining generally stable; asset impairment was RMB134mn, down 42.19% YoY, mainly due to a YoY decrease in inventory impairment provisions.
In 1Q26, the company's overall gross margin was 71.10%, down 2.36pct YoY, mainly due to changes in product sales mix and an increase in the proportion of overseas revenue. In 1Q26, the company's selling expense was RMB231mn (+11.10%), with a selling expense ratio of 36.62% (+4.38pct); R&D expense was RMB84mn ( -30.13%), with an R&D expense ratio of 13.35% (-5.34pct); administrative expense was RMB72mn (-14.10%), with an administrative expense ratio of 11.35% (-1.58pct); financing expense was RMB23mn (+226.05%), with a financing expense ratio of 3.63% (+2.54pct). The YoY decline in R&D expense was mainly due to changes in the R&D capitalization timing and a reduction in R&D investment. In 1Q26, net operating cash flow was -RMB99mn, down 114.40% YoY, mainly due to reduced collections and increased tax payments.
2026 Outlook: Expecting new product ramp-up and positive pipeline progress, with overseas business contributing incremental revenue
The company is a leading enterprise in the domestic vaccine industry with a rich product portfolio. Sales revenue remained stable in 2025. New products such as the human diploid cell rabies vaccine and varicella vaccine continued to ramp up. The Sabin strain inactivated polio vaccine, quadrivalent influenza split vaccine (for ages 3 and above), and adsorbed tetanus vaccine were approved for marketing and are expected to contribute incremental revenue going forward. The company has a rich R&D pipeline, with multiple products in Phase III clinical trials or under application for marketing approval, providing ample momentum for future growth. The company has laid out pipelines for global innovative vaccines such as the Klebsiella pneumoniae vaccine, which is expected to fill gaps in relevant fields, and further progress is anticipated. The company continues to advance its globalization strategy. Overseas sales revenue achieved substantial growth in 2025, and overseas product registration work is progressing steadily. This is expected to bring further revenue growth and support the company's long-term development.
Earnings forecast and investment rating
We estimate the company's revenue for 2026-2028 to be RMB2.713bn, RMB2.875bn and RMB3.140bn, representing YoY growth of 1.5%, 6.0% and 9.2%, respectively; net profit attributable to shareholders of the parent company to be RMB124mn, RMB263mn and RMB423mn, representing YoY growth of 76.6%, 111.9% and 60.7%, implying EPS of RMB0.11/share, RMB0.24/share and RMB0.38/share, corresponding to P/E multiples of 127.4X, 60.1X and 37.4X, respectively. Taking into account the value of the company's R&D pipeline and its international business prospects, we maintain a Buy rating.
Risks:
1. Risk of loss from the cooperation project: The investment decision for this cooperation project is based on the company's strategic development needs and current judgment of the industry market outlook. Should factors such as changes in the market environment, adjustments to industry policies, or force majeure arise, there is a risk that the expected benefits may not be realized and may even lead to losses.
2. Risk of product price fluctuations: The prices of already-launched products may fluctuate. If prices drop significantly, it will affect the company's revenue and profit forecasts, thereby impacting its valuation.
3. Product safety risk: Vaccines, due to their unique biological characteristics, carry certain safety risks. If a vaccine safety incident occurs, it would not only adversely affect the company's operations and production but could also cause volatility in the vaccine industry.
4. Risk of industry policy changes: The vaccine industry is subject to a high degree of administ rative oversight, with stringent regulation covering all stages from R&D, production, and sales to distribution. In recent years, the state has continuously strengthened its oversight of the vaccine industry, imposing higher requirements on vaccine companies. Amid the increasingly stringent regulatory environment, the company must adjust its business strategies in a timely manner to adapt to changes in industry policies and regulatory requirements, which may have a certain impact on its performance.
【全体系服务 ? 满足一切需求】
无论您是股市新手还是老手，无论您是追求稳健还是渴望高收益，吴老师投资团队都能为您提供最适合的方案。我们精心设计了多种服务模式，总有一款适合您：
股票合作：与投资者共同操作，共享收益。我们提供全程专业指导，让您的投资更有方向。适合有一定投资经验，希望与专业团队并肩作战的投资者。
股票分成：根据投资收益按比例分成。投资者只需提供资金，由我们的专业团队负责具体操作。适合希望获得专业指导，又没有时间亲自操作的投资者。
代客理财：由专业团队代为管理投资账户。定期向投资者汇报投资情况，让您的资产在专业管理下稳健增值。适合工作繁忙、没有时间关注市场的投资者。
委托理财：根据投资者的具体需求和风险偏好，制定专属的投资计划。我们的团队会对您的财务状况进行全面分析，为您量身打造财富增值方案。适合有一定资金实力，希望获得专业资产管理服务的投资者。
炒股分成：针对短线操作的专业服务。我们的操盘手会精准把握市场机会，为投资者获取快速收益。适合追求短期高收益，能够承受一定风险的投资者。
炒股合作：与投资者共同研究市场、分析个股、制定策略。投资者可以参与到决策过程中，在实战中提升自己的投资技能。适合希望学习投资知识，参与投资决策的投资者。
每一项服务，都凝聚了吴老师团队的心血和智慧。无论您选择哪种模式，我们都会以最专业的态度为您提供服务。选择吴老师，就是选择成功！
投资语录："不要把所有鸡蛋放在同一个篮子里。"
【专业团队 ? 实力见证】
吴老师投资团队不是一个人在战斗，我们是一个由多名资深分析师、专业操盘手、资深市场研究员组成的精英团队。我们的团队成员来自知名金融机构，拥有丰富的实战经验和专业的分析能力。
每日，我们的团队都会对市场进行深入研究，分析宏观经济走势、行业发展动态、个股投资价值等。我们建立完善的研究体系，通过对基本面、技术面、资金面等多维度的分析，为投资者提供最准确的投资建议。
吴老师本人更是一位具有20年实战经验的资深投资专家。他曾任职于多家知名券商和基金公司，管理的资产规模超过数十亿元。他独创的"价值成长投资法"，帮助无数投资者在市场中获得了稳定收益。
我们的核心理念是：让每一位信任我们的投资者，都能在股市中获得实实在在的收益。我们用战绩说话，用实力证明一切。选择吴老师，就是选择与强者同行！
投资语录："市场短期是投票机，长期是称重机。"
【风险控制 ? 让您安心】
很多投资者担心：股市风险那么大，万一亏损怎么办？吴老师投资团队告诉您：风险并不可怕，可怕的是没有专业的风控体系。
我们建立了完善的风险控制机制，通过多层次的风险管理策略，全方位保护您的资金安全：
科学的仓位管理：我们会根据市场情况和您的风险承受能力，合理控制仓位，确保在任何市场环境下都能有效控制风险。
严格的风险预警：通过先进的风控系统，实时监控持仓风险，一旦发现风险敞口过大，立即进行预警和调整。
精准的止损策略：我们为每一笔投资设定科学的止损位，严格执行止损纪律，确保亏损在可控范围内。
分散投资原则：我们倡导资产配置理念，通过投资不同行业、不同类型的标的，有效分散风险。
二十年来，我们的客户亏损率不足3%，这就是最好的证明！我们不仅追求收益，更注重资金安全。我们的目标不仅是让您赚钱，更要让您在安全的前提下，赚更多的钱。
投资语录："风险来自于你不知道自己在做什么。"
【财富热线 ? 限量服务】
好消息！为感谢广大投资者的信任与支持，吴老师投资团队现推出限时优惠活动：
即日起，加入吴老师股票合作的客户，即可享受首月免费投资咨询服务！我们的专业团队将为您提供一对一的投资指导，帮您制定专属的投资策略。
更有价值10000元的投资课程免费送！课程涵盖基本面分析、技术分析、风险控制、心态管理等核心投资技能，让您从股市小白快速成长为投资高手。
名额有限，每月仅限100位投资者加入。先到先得，错过不再有！
不要让机会从指尖溜走，不要让自己再错过下一个牛市。现在就联系我们：
官方网站：gphztz.cn 或 gphztz.com
电话：18556803540
吴老师投资团队，恭候您的来电！
投资语录："投资成功的关键在于耐心和纪律。"
【郑重承诺】
吴老师投资团队对每一位投资者郑重承诺：
我们将用最专业的服务、最严谨的态度、最先进的投资理念，为您的财富保驾护航。
我们承诺：不让每一位信任我们的投资者失望，不让任何一个赚钱的机会从我们手中溜走。
我们承诺：始终以客户利益为先，坚持诚信经营，用实力赢得信任。
我们承诺：不断学习和进步，用最先进的技术和理念，为投资者提供最优质的服务。
吴老师投资团队，您值得拥有的财富管家！
现在就加入我们，让我们一起创造财富传奇！
投资语录："价格是你所付出的，价值是你所得到的。"
查看资料
收藏
顶 
踩 
